Drug Discovery Featured Articles & Applications

41. Should My Biotech Startup Buy Or Produce The Proteins We Use? 6/1/2023

    "Should we build out an internal group of scientific expertise or delegate work to external vendors?" It's a question that this author has faced in his career. He shares key considerations for building protein science teams.

42. How Predictive Can Regulatory Drug Abuse Potential Investigations Be in Animals? 5/31/2023

    Is addiction attributed to “the animal or the human within us” or is substance abuse unique to humans? This question has intrigued me since the EMA guidance on Non-clinical Investigation of the Dependence Potential of Medicinal Products in 2006 and the FDA guidance on Assessment of Abuse Potential of Drugs in 2010 have requested the performance of dedicated studies in animals. Let's take a closer look at the matter.

43. The Global Market For AI In Drug Discovery To Sextuple By 2027 5/26/2023

    The integration of artificial intelligence (AI) in drug discovery has been a game-changer, significantly improving efficiency and accuracy, and its use is growing exponentially. This article shares market drivers, market restraints, and emerging trends.

44. The 2 Factors Driving A Surge In Aptamer Use In Drug Discovery 5/25/2023

    Aptamers offer advantages over antibodies, including lower immunogenicity and toxicity, better tissue penetration, lower production costs, and a very long shelf life. Why, then, have we not seen more of these come to market? Two hurdles have stood in the way until recently.

45. FDA Adopts ICH Guidance On Assessing Nonclinical Biodistribution Of Gene Therapy Viral Vectors 5/23/2023

    An important step in the gene therapy development process is assembling biodistribution data in suitable animals in relation to the intended clinical population. Developing an accurate biodistribution profile is influenced by factors such as the route of administration, dose level(s), dosing regimen, and the animal immune response to the gene therapy product. The FDA adopted this ICH guidance in May 2023, and the EMA plans to adopt it in September 2023.

46. Optimizing Digitalization To Accelerate Your R&D 5/19/2023

    Drug/therapy development has made significant leaps in innovation in recent years, but common issues that hinder progress still exist. Are you harnessing and optimizing your data for speedier drug development and quicker launch timescales? This article shares important recommendations.

47. Leveraging AI In Drug Discovery To Treat MS & Other Autoimmune Diseases 5/17/2023

    The advancement of artificial intelligence and machine learning algorithms means we can use large pools of genetic data to identify potential risk factors and disease-causing genes for multiple sclerosis and other autoimmune diseases. This author shares a three-pronged approach to analyzing data for AI algorithms, pitfalls to avoid, and AI for silico modeling.

48. Key Considerations For Developing Next-Generation Antibody-Drug Conjugates 5/11/2023

    Fourteen antibody-drug conjugates (ADCs) have been approved globally for cancer indications so far. This article shares considerations for complementing target with antibody subtype, optimizing format for half-life functionality, and delivering payloads with diverse MOA.

49. India’s CROs & CDMOs Come Of Age In The Global Marketplace 5/4/2023

    Most of the top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug development, and/or manufacturing done in India. While a low price is the initial attraction, there are additional factors that can be more meaningful.

50. 5 Characteristics Of The Automated Microbiology Lab Of The Future 4/24/2023

    The modern microbiology laboratory is starting to look very different from the laboratory of 10 years ago, and it will continue to evolve in the next few years. There are a number of innovations being implemented now or are in progress that can signal the path that many microbiology laboratories will follow.